Why Drug Overdose Deaths Are Falling – A Closer Look

From 2021 through 2023, more than 105,000 Americans died each year from a drug overdose – numbers that dwarfed the already grim pre‑COVID rates. Then, almost out of nowhere, the curve turned.

In 2024 the national death toll fell by 27%, and early figures from 2025 suggest the trend is continuing, albeit from a still‑high baseline. The pattern isn’t confined to the United States; Scotland reported a 13% dip and Canada a 9% reduction in the same period.

“It’s unprecedented to see overdose deaths come down so dramatically, so quickly,” says Brandon Marshall, an epidemiologist at Brown University. Still, he cautions that the crisis is far from over.

What caused the drop? Nobody knows for sure. Evan Gumas, a senior research associate at the Commonwealth Fund, spent weeks talking to public‑health officials in more than two dozen U.S. states and several other nations. His new report, released Thursday, finds a common thread – but no single silver bullet.

“Every interview I did kept circling back to the same handful of initiatives,” Gumas explains. Those include widespread naloxone distribution, broader access to medication‑assisted treatment, better care for people behind bars, and a more robust data infrastructure that lets officials spot trouble spots faster.

One of the most concrete contributors appears to be the overdose‑reversal drug naloxone. In 2022, SAMHSA required states that received opioid‑response funding to devise “naloxone saturation” plans. Virginia, for example, rolled out such a plan and saw a 40% drop in overdose deaths the following year. Maryland doubled its naloxone distribution between 2021 and 2025 – even installing vending machines and training first‑responders to hand the drug to bystanders – and cut its death rate by roughly a quarter.

Access to medications for opioid use disorder (MOUD) like methadone and buprenorphine is also improving, though it’s still far from optimal. Gumas argues that Medicaid expansion is the single most influential lever for expanding MOUD coverage. Colorado’s methadone clinics more than doubled in five years, and New York witnessed a similar surge. Across the Atlantic, Swedish health authorities credit a decade of MOUD expansion with a 25% fall in deaths since 2017.

Prison‑based treatment reforms are another piece of the puzzle. Substance‑use disorders are about twelve times more common in incarcerated populations, and the weeks after release are a lethal window. In New York, the use of MOUD in prisons and jails jumped seven‑fold between 2022 and 2025, a change that many experts say directly saved lives.

That said, some sobering context remains. “So many people died during the years of accelerating fatalities that the pool of people at highest risk has shrunk a bit,” notes addiction‑medicine physician Sarah Wakeman. Moreover, the illicit drug supply is in constant flux; the potency of fentanyl, for instance, has tapered off slightly in recent years, an effect that’s hard to track but may be nudging the numbers down.

Looking ahead, the gains are fragile. Potential Medicaid cuts and a federal administration that, while supportive of medication‑based treatment, pushes back against certain harm‑reduction measures could stall or reverse progress. As Gumas emphasizes, “we’re nowhere near out of this crisis,” but the recent dip offers a glimmer of hope and a roadmap for what might work if we stay the course.